Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas

Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. Aldoxorubicin is a prodrug of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Yan, Jessica, Forscher, Charles, Hendifar, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896668/
https://www.ncbi.nlm.nih.gov/pubmed/29670334
http://dx.doi.org/10.2147/DDDT.S140638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896668/
https://www.ncbi.nlm.nih.gov/pubmed/29670334
http://dx.doi.org/10.2147/DDDT.S140638

Ejemplares similares